MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a medical know-how firm targeted on remodeling the lives of individuals residing with epilepsy, as we speak issued the next assertion in response to the Facilities for Medicare & Medicaid Providers (CMS) electing to not finalize its proposed reassignment of epilepsy with neurostimulator circumstances within the FY 2026 Inpatient Potential Fee System (IPPS) rule.
“We admire CMS’ openness to public touch upon the proposed rule and its reconsideration of the unique proposal to reassign RNS circumstances to MS-DRG 020-022. We commend CMS’ choice to keep up the present MS-DRG task for RNS® System procedures beneath MS-DRG 023,” mentioned Joel Becker, Chief Govt Officer of NeuroPace. “This maintains continuity for hospitals offering the RNS System to Medicare beneficiaries, who symbolize a susceptible and underserved epilepsy inhabitants.”
NeuroPace will proceed to work with CMS on MS-DRG enhancements and different reimbursement associated matters. The corporate stays dedicated to making sure that reimbursement coverage retains tempo with scientific innovation and that entry to the RNS System is accessible for all who might profit.
About NeuroPace, Inc.
Primarily based in Mountain View, Calif., NeuroPace is a medical gadget firm targeted on remodeling the lives of individuals residing with epilepsy by decreasing or eliminating the prevalence of debilitating seizures. Its novel and differentiated RNS System is the primary and solely commercially out there, brain-responsive platform that delivers personalised, real-time remedy on the seizure supply. This platform can drive a greater normal of care for sufferers residing with drug-resistant epilepsy and has the potential to supply a extra personalised answer and improved outcomes to the massive inhabitants of sufferers affected by different mind problems.
Ahead Trying Statements
This press launch might include forward-looking statements made pursuant to the secure harbor provisions of the Personal Securities Litigation Reform Act of 1995. These statements could also be recognized by phrases similar to “goals,” “anticipates,” “believes,” “may,” “estimates,” “expects,” “forecasts,” “objective,” “intends,” “might,” “plans,” “potential,” “potential,” “seeks,” “will” and variations of those phrases or comparable expressions which can be meant to determine forward-looking statements, though not all forward-looking statements include these phrases. NeuroPace might not truly obtain the plans, intentions or expectations disclosed in these forward-looking statements, and you shouldn’t place undue reliance on these forward-looking statements. Ahead-looking statements on this press launch embrace, however should not restricted to, statements concerning: the outcomes of NeuroPace’s continued work with CMS on Medicare reimbursement for the RNS System. Precise outcomes or occasions may differ materially from the plans, intentions and expectations disclosed in these forward-looking statements on account of varied elements, together with: dangers associated to the pricing of the RNS System and availability of ample reimbursement for the procedures to implant the RNS System and for clinicians to offer ongoing care for sufferers handled with the RNS System. These and different dangers and uncertainties embrace these described extra totally within the part titled “Danger Elements” and “Administration’s Dialogue and Evaluation of Monetary Situation and Outcomes of Operations” and elsewhere in NeuroPace’s public filings with the U.S. Securities and Alternate Fee (SEC), together with its Quarterly Report on Type 10-Q for the quarter ended March 31, 2025, filed with the SEC on Might 13, 2025, in addition to another reviews that it could file with the SEC sooner or later. Ahead-looking statements contained on this announcement are based mostly on data out there to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to replace such data besides as required beneath relevant legislation. These forward-looking statements shouldn’t be relied upon as representing NeuroPace’s views as of any date subsequent to the date of this press launch and shouldn’t be relied upon as a prediction of future occasions. In gentle of the foregoing, traders are urged to not depend on any forward-looking assertion in reaching any conclusion or making any funding choice about any securities of NeuroPace.
Investor Contact:
Scott Schaper
Head of Investor Relations
sschaper@neuropace.com
traders@neuropace.com
Source link
#NeuroPace #Commends #CMS #Maintaining #FY25 #Reimbursement #Structure #Epilepsy #Neurostimulator #Cases
